These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9140272)

  • 1. Clinical adrenal insufficiency in patients receiving megestrol therapy.
    Subramanian S; Goker H; Kanji A; Sweeney H
    Arch Intern Med; 1997 May; 157(9):1008-11. PubMed ID: 9140272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megestrol acetate therapy and secondary adrenal suppression.
    Naing KK; Dewar JA; Leese GP
    Cancer; 1999 Sep; 86(6):1044-9. PubMed ID: 10491532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer.
    Dev R; Del Fabbro E; Bruera E
    Cancer; 2007 Sep; 110(6):1173-7. PubMed ID: 17647248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megestrol acetate-associated adrenal insufficiency.
    Bulchandani D; Nachnani J; Amin A; May J
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):167-72. PubMed ID: 18775392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megestrol acetate-induced adrenal insufficiency.
    González Villarroel P; Fernández Pérez I; Páramo C; Gentil González M; Carnero López B; Vázquez Tuñas ML; Carrasco Alvarez JA
    Clin Transl Oncol; 2008 Apr; 10(4):235-7. PubMed ID: 18411198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial.
    Reuben DB; Hirsch SH; Zhou K; Greendale GA
    J Am Geriatr Soc; 2005 Jun; 53(6):970-5. PubMed ID: 15935019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II trial evaluating the effect of megestrol acetate-prednisolone combination in the treatment of anorexia during the palliative-care phase of lung cancer].
    Jeanfaivre T; Souday V; Chaleil D; Maillet F; Tuchais E
    Rev Pneumol Clin; 2000 Sep; 56(4):255-60. PubMed ID: 11033533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast.
    Ansfield FJ; Kallas GJ; Singson JP
    Surg Gynecol Obstet; 1982 Dec; 155(6):888-90. PubMed ID: 7147170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
    Lundgren S; Helle SI; Lonning PE
    Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excessive sweating: unusual side effect of megestrol acetate therapy.
    Votaw ML
    Tenn Med; 1997 Feb; 90(2):59. PubMed ID: 9029997
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adrenal function after induction of cardiac surgery patients with an etomidate bolus: a retrospective study].
    Seravalli L; Pralong F; Revelly JP; Que YA; Chollet M; Chioléro R
    Ann Fr Anesth Reanim; 2009 Sep; 28(9):743-7. PubMed ID: 19683891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
    Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
    Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
    Bland KI; Buzdar AU
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):12S-13S. PubMed ID: 10619454
    [No Abstract]   [Full Text] [Related]  

  • 14. Dynamic evaluation of adrenal hypofunction.
    Nieman LK
    J Endocrinol Invest; 2003; 26(7 Suppl):74-82. PubMed ID: 14604069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary symptomatic adrenal insufficiency induced by megestrol acetate.
    Delitala AP; Fanciulli G; Maioli M; Piga G; Delitala G
    Neth J Med; 2013 Jan; 71(1):17-21. PubMed ID: 23412818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.
    Matin K; Egorin MJ; Ballesteros MF; Smith DC; Lembersky B; Day RS; Johnson CS; Trump DL
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):179-85. PubMed ID: 12203099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy.
    Payne JK; Held J; Thorpe J; Shaw H
    Oncol Nurs Forum; 2008 Jul; 35(4):635-42. PubMed ID: 18591167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megestrol-induced clinical adrenal insufficiency.
    Goodman A; Cagliero E
    Eur J Gynaecol Oncol; 2000; 21(2):117-8. PubMed ID: 10843465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.
    Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):482-6. PubMed ID: 13680163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal insufficiency and testicular failure secondary to megestrol acetate therapy in a patient with cystic fibrosis.
    McKone EF; Tonelli MR; Aitken ML
    Pediatr Pulmonol; 2002 Nov; 34(5):381-3. PubMed ID: 12357484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.